1409 completed, 257 recruiting, 250 unknown, 215 terminated. 761 Phase 2, 699 Phase 1, 331 Phase 3, 308 Not applicable, 131 Phase 4.
Follow Herpesviridae Infections: new trials by email Literature Review of Herpesviridae Infections trials Research Report on Herpesviridae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Study Of KITE-753 in R/R B-Cell ALL KITE-753 - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 18 | 2026-12-31 | 2026-09-11 |
| Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults MVA-BN-EBV, Placebo - Epstein Barr Virus (EBV) Infection | Phase 1 | Not yet recruiting | Bavarian Nordic | 15 | 2026-12-15 | 2026-10-22 |
| Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia Rituximab - PTLD, Epstein Barr Virus (EBV) Infection | Phase 1 | Not yet recruiting | Jennifer Amengual | 28 | 2026-12-01 | 2026-09-17 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2026-12-01 | 2026-10-22 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults VXCO-102, Placebo - EBV | Phase 1 | Recruiting | Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company | 82 | 2026-11-16 | 2026-10-26 |
| EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases Donor-derived ex-vivo expanded EBV Tscm CTL - EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Basel, Switzerland | 10 | 2026-11-01 | 2025-03-03 |
| Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II Valganciclovir, Ganciclovir (GCV), Placebo - Cytomegalovirus (CMV), Anterior Uveitis | Phase 2 | Not yet recruiting | University of California, San Francisco | 117 | 2026-11-01 | 2026-08-11 |
| 25BT056: Basket Study of Viral Cytotoxic T Lymphocytes Virus-Specific Cytotoxic T Lymphocytes (vCTLs) - EBV Viremia, CMV Viremia | Early Phase 1 | Not yet recruiting | Children's Hospital of Philadelphia | 35 | 2026-11-01 | 2026-10-22 |
| Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia Fludarabine, Cyclophosphamide, Levetiracetam - CD19 Positive, B-ALL | Phase 1 | Not yet recruiting | Medical University of South Carolina | 18 | 2026-11-01 | 2026-10-26 |
| Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above Recombinant Zoster Vaccine (CHO cell) SYS6052, Placebo: 0.9% sodium chloride injection, Active Comparator Vaccine - Herpes Zoster | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 496 | 2026-10-31 | 2026-10-23 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events Placebo, Adjuvanted RZV vaccine, Adjuvanted RSVPreF3 vaccine - Cardiovascular Disease | Phase 2 | Not yet recruiting | GlaxoSmithKline | 450 | 2026-10-23 | 2026-10-20 |
| Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial Two-dose M0-M2 vaccination schedule, Two-dose M0-M6 vaccination schedule - Vaccine, Varicella-zoster Virus | Phase 4 | Not yet recruiting | University Hospital, Toulouse | 160 | 2026-10-20 | 2026-09-14 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
Showing 20 of 2423. Sign in to see all of them.
Burkitt Lymphoma (974) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (590) · Lymphoma, Large B-Cell, Diffuse (574) · Lymphoma, Follicular (523) · Lymphoma, Non-Hodgkin (513) · Lymphoma, Mantle-Cell (508) · Leukemia, Lymphocytic, Chronic, B-Cell (468) · Lymphoma, B-Cell, Marginal Zone (458) · Lymphoma (457) · Lymphoma, Large-Cell, Immunoblastic (445) · Cytomegalovirus Infections (369) · Hodgkin Disease (360) · Herpes Zoster (276) · Leukemia (269) · Leukemia, Myeloid, Acute (255)
DNA Virus Infections (2413) · Virus Diseases (2380) · Infections (2368) · Immune System Diseases (1311) · Neoplasms by Histologic Type (1182) · Tumor Virus Infections (1148) · Neoplasms (1132) · Hemic and Lymphatic Diseases (1079) · Lymphatic Diseases (1055) · Immunoproliferative Disorders (1050) · Lymphoproliferative Disorders (1004) · Epstein-Barr Virus Infections (976) · Lymphoma, B-Cell (908) · Pathological Conditions, Signs and Symptoms (813)
Cyclophosphamide (227) · Rituximab (122) · Etoposide (109) · Vincristine (102) · Methotrexate (96) · Peripheral Blood Stem Cell Transplantation (96) · Filgrastim (95) · Cytarabine (93) · fludarabine phosphate (86) · Doxorubicin (83) · Prednisone (75) · Radiotherapy (68) · Dexamethasone (64) · Ganciclovir (63) · Mycophenolic Acid (63)
National Cancer Institute (NCI) (152) · National Institute of Allergy and Infectious Diseases (NIAID) (111) · GlaxoSmithKline (100) · Fred Hutchinson Cancer Center (62) · Merck Sharp & Dohme LLC (59) · M.D. Anderson Cancer Center (36) · City of Hope Medical Center (34) · Memorial Sloan Kettering Cancer Center (34) · University of Washington (26) · Children's Oncology Group (25) · Masonic Cancer Center, University of Minnesota (25) · Hoffmann-La Roche (24) · Case Comprehensive Cancer Center (23) · Assistance Publique - Hôpitaux de Paris (20) · AIDS Malignancy Consortium (18)
United States (1354) · China (249) · Canada (143) · France (138) · United Kingdom (103) · Germany (99) · Italy (98) · Spain (79) · Australia (78) · Belgium (58) · South Korea (54) · Switzerland (43) · Puerto Rico (40) · Brazil (38) · Netherlands (38)
Robert Yarchoan, M.D. (11) · Ajay Gopal (9) · Anna Wald, MD, MPH (9) · Ramya M Ramaswami, M.D. (8) · Elias Jabbour (7) · Helen E Heslop, MD (7) · Connie Celum, MD, MPH (6) · Philip L. McCarthy, MD (6) · Christos E. Emmanouilides, MD (5) · David Maloney (5)
PMID 41671463, PMID 37781954, PMID 38700045, PMID 39807668, PMID 35622074, PMID 34515338, PMID 32499241, PMID 22225814, PMID 31042791, PMID 32589970, PMID 36066965, PMID 37166199, PMID 38551807, PMID 40237463, PMID 40396505, PMID 17242396, PMID 19273678, PMID 19949018, PMID 20028764, PMID 20353469, PMID 21527516, PMID 21991950, PMID 22002018, PMID 22337718, PMID 23196955, PMID 24862638, PMID 26343451, PMID 27037091, PMID 27851688, PMID 29955836, PMID 30596974, PMID 30935742, PMID 31537443, PMID 32347767, PMID 32504089, PMID 32665955, PMID 32910152, PMID 33308471, PMID 33496754, PMID 33606577, PMID 34353848, PMID 34432863, PMID 34473237, PMID 34687939, PMID 34806163, PMID 34889384, PMID 35142535, PMID 35422096, PMID 35489026, PMID 35732829
P30CA033572 (25), P30CA015704 (20), P30CA043703 (18), U10CA032102 (15), P30CA006973 (13), P30CA015083 (12), U10CA180886 (12), 2023 (11), P30CA022453 (11), U01CA121947 (11), 2017 (10), 2025 (9), P30CA072720 (9), U01CA097452 (9), U10CA098543 (9)